Jaime Merchan, MD

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

Jaime Merchan, MD, discusses the background and findings from the LITESPARK-013 trial of belzutifan for the treatment of patients with advanced clear cell renal cell carcinoma.

Jaime Merchan, MD, discusses what the potential clinical implications or takeaways for colleagues are based on findings from the phase 3 CLEAR study in advanced renal cell carcinoma (RCC).

Jaime Merchan, MD, discusses findings from an analysis presented at the 2024 ASCO Meeting.